10x Genomics, Inc. Form 8-K Summary
Business context and reporting period
The Form 8-K, filed June 16, 2023, reports the results of 10x Genomics, Inc.’s annual meeting of stockholders held June 14, 2023, by live webcast. Holders representing approximately 85.48% of eligible voting power were present virtually or by proxy, establishing a quorum.
Key financial metrics
This filing concerns corporate governance matters and does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating or financial metrics.
Material changes versus the prior comparable period
The filing does not report comparative financial or operating changes. Stockholders elected three Class I directors, ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, and approved executive compensation on a non-binding advisory basis.
Guidance, outlook, risks, contingencies, and unusual items
- Benjamin J. Hindson, Serge Saxonov, and John R. Stuelpnagel were elected to three-year terms expiring at the 2026 annual meeting or until their successors are elected and qualified.
- Ernst & Young LLP’s appointment for fiscal 2023 was ratified by 238,169,533 votes for, 71,101 against, and 71,725 abstentions.
- Named executive officer compensation was approved on an advisory basis by 188,319,036 votes for, 39,091,966 against, and 116,605 abstentions.
- No new guidance, outlook, contingencies, or unusual financial items were disclosed.
Important facts for investors to verify
- Review the detailed director-election vote totals, including broker non-votes.
- Confirm the scope and terms of the executive compensation programs in the definitive proxy statement filed April 28, 2023.
- Review subsequent filings for any changes to the board, auditor relationship, or executive compensation arrangements.